Exabis Library
Welcome to the e-CCO Library!
P570: Current status of the effectiveness of infliximab in patients with ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P570: Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: Results from GEMINI trial data
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P570: Kock pouches in the 21st century: a descriptive study of short-term (30-day) outcomes in a national cohort of 177 patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P570: Prediction of achieving remission in Crohn's disease patients by abdominal Imaging
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P570: Prevalence and risk factors for intestinal resection in patients with Crohn’s disease in a Greek referral center
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P570: Safety and Effectiveness of Tofacitinib in Ulcerative Colitis: Real-world Data from TOFA-UC, a SN-IBD Study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P571 Self-Medication with steroids in ulcerative colitis: Results of a patient survey
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P571: Can Crohn's colits be cured by surgery?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P571: Effectiveness and safety of Ustekinumab for induction of remission in patients with Crohn's disease: a multi-centre Israeli study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P571: Frequency and risk factors of advanced neoplasia in Korean IBD patients with Low Grade Dysplasia in previous surveillance
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P571: Optimal biologic management of endoscopic postoperative recurrence following ileocecal resection in Crohn’s disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P571: The Nordic diet as a tool to improve the activity of disease and psycho-emotional wellbeing in patients with mild and moderate Ulcerative Colitis – the pilot study.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P571: Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P572 Clinical outcomes after discontinuation of anti-tumour necrosis factor-α agents in inflammatory bowel disease patients with clinical remission: KASID multicenter study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P572: Coexisting Inflammatory bowel disease and Ankylosing spondylitis: Management and clinical outcomes
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P572: Half of children with acute severe colitis have predominant single faecal bacterial species, mostly Escherichia coli: Microbiome results from the PRASCO trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P572: Medical therapies for stricturing Crohn's disease: efficacy and cross-sectional imaging predictors of therapeutic failure
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P572: Reactive dose escalation of infliximab in patients with Crohn’s disease in TAILORIX leads to improved outcomes
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P572: The influence of beliefs about medication in therapeutic adherence among patients with inflammatory bowel disease.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P572: Therapy optimisation and intravenous ferric carboxymaltose in active or inactive IBD with iron deficiency: it's time to make iron deficiency part of tight monitoring to reach T2T? – preliminary results of a prospective study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM